Lancet Oncol. 2024
Lin Y, Qiu L, Usmani S, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O’Dwyer M, Schjesvold F, Sidana S, van de Donk NWCJ, Weisel K, Zweegman S, Raje N, Rodriguez Otero P, Anderson Jr LD, Kumar S, Martin T, International Myeloma Working Group. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024;25(8):e374-e387.
Chimeric Antigen Receptor T-cell (CAR T-cell) therapy has emerged as a transformative treatment for relapsed or refractory multiple myeloma (R/R MM), which remains challenging despite advances in conventional therapies.1 Targeting B-cell m
May 26, 2025
